PhysEmp :: Medicine :: Medical Specialties :: Gastroenterology (10)

All Gastroenterology Jobs

University City :: Kentucky :: Medical Search Consultants
Join Group of 2 This is an excellent opportunity for a BE/BC Gastroenterologist to join 2 others as an expansion to this very busy practice. The group has a very loyal referral base that is sending
Coastal Georgia :: Georgia :: Medical Search Consultants
HOSPITAL EMPLOYEE OR INCOME GUARANTEE This is an excellent opportunity for a BE/BC Gastroenterologist to join 2 others in a very busy regional medical center practice setting. This is a high-volume
Great Location :: Florida :: Intelligent Placement Solutions, Inc
Join a 2 person single specialty practice. The surgical center is ownd by multiple physicians. Buy in is an option. Call is 1:4 Less that 10% of patients come from the hospitals. This is a two year

FeedNavigator - Journals - Gastroenterology

A 10-year large-scale cystic fibrosis carrier screening in the Italian population
Journal of Cystic Fibrosis / Terkko Sun, 08 Nov 2009 00:00:05 +0200

Polycystins play a key role in the modulation of cholangiocyte proliferation?
Digestive and Liver Disease / Terkko Sat, 07 Nov 2009 23:30:13 +0200

Endoscopic Ultrasound-guided cholangiopancreatography and rendezvous techniques
Digestive and Liver Disease / Terkko Sat, 07 Nov 2009 23:30:13 +0200

Marqueurs non invasifs de fibrose dans la maladie alcoolique du foie
Gastroentérologie Clinique et Biologique / Terkko Sat, 07 Nov 2009 23:29:54 +0200

Effects of the Gastrin-Releasing Peptide Antagonist RC-3095 in a Rat Model of Ulcerative Colitis.
Digestive Diseases and Sciences / Terkko Sat, 07 Nov 2009 13:18:20 +0200

The London OMED position statement for credentialing and quality assurance in digestive endoscopy
Endoscopy / Terkko Sat, 07 Nov 2009 04:05:00 +0200


pubmed: 1542-3565

Response to Letter to the Editor Re: A Very Low-carbohydrate Diet Improves Symptoms and Quality of Life in Diarrhea-Predominant Irritable Bowel Syndrome.
Austin GL, Dalton CB, Hu Y, Morris CB, Hankins J, Weinland SR, Westman EC, Yancy WS, Drossman DA Related Articles Response to Letter to the Editor Re: A Very Low-carbohydrate Diet Improves Symptoms and Quality of Life in Diarrhea-Predominant Irritable Bowel Syndrome. Clin Gastroenterol Hepatol. 2009 Nov 2; Authors: Austin GL, Dalton CB, Hu Y, Morris CB, Hankins J, Weinland SR, Westman EC, Yancy WS, Drossman DA PMID: 19892037 [PubMed - as supplied by publisher]
Reply Letter: Thank you for your interest in our work.
Kallwitz ER Related Articles Reply Letter: Thank you for your interest in our work. Clin Gastroenterol Hepatol. 2009 Nov 2; Authors: Kallwitz ER PMID: 19892036 [PubMed - as supplied by publisher]

Nature Reviews Gastroenterology and Hepatology - Issue - nature.com science feeds

Great (cultural) expectations
Stephen B. HanauerI consider myself to be quite fortunate. I enjoy being able to travel and observe different cultures. This has been the case since early in my professional career and doesn't apply to international travel alone. I recall excursions to various locations within the US—rural and
Celiac disease: Progress towards noninvasive diagnosis and follow-up
Natalie J. Wood Celiac disease: Progress towards noninvasive diagnosis and follow-up Nature Reviews Gastroenterology & Hepatology 6, 625 (2009). doi:10.1038/nrgastro.2009.174 Author: Natalie J. Wood
IBS: Soluble fiber benefits patients with IBS
Rachel Jones IBS: Soluble fiber benefits patients with IBS Nature Reviews Gastroenterology & Hepatology 6, 626 (2009). doi:10.1038/nrgastro.2009.170 Author: Rachel Jones

Inflammatory Bowel Diseases

Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis
Milan Lukas, Pavel Drastich, Michal Konecny, Paolo Gionchetti, Ondrej Urban, Franco Cantoni, Martin Bortlik, Dana Duricova, Michael Bulitta Mon, 02 Nov 2009 10:09:00 -0000
Increased activity of intestinal alkaline phosphatase (AP) occurs locally in patients with ulcerative colitis (UC), aimed at repairing inflammatory tissue damage. We evaluated the safety and preliminary efficacy of exogenous AP administered to patients with UC in an open-label, first-in-patient exploratory trial, conducted in the Internal Medicine and Gastroenterology hospital departments in the Czech Republic and Italy.Twenty-one patients were enrolled (13 females), age 23-54 years, with steroid- and/or immunosuppressant-refractory, moderate/severe UC (Mayo score 6-11). Oral AP enzyme 30,000 U was administered daily for 7 days, intraduodenally. Efficacy outcomes were changes in Mayo score at Day 21 posttreatment; changes in Modified Truelove-Witts Severity index (MTWSI) at Days 21, 63; C-reactive protein and stool calprotectin levels at Days 7, 21, 63. Safety evaluations were adverse events and laboratory abnormalities reported up to Day 63 posttreatment.No clinically relevant adverse events causing withdrawal or considered serious, or laboratory abnormalities or antibody formation against AP were observed. Mayo scores were significantly decreased at Day 21, and MTWSI at Days 21 and 63. C-reactive protein and stool calprotectin levels were decreased at Days 21 and 63. Clinical response on the Mayo score after a single 7-day AP course was 48% at Day 21.In this uncontrolled trial, administration of exogenous AP enzyme daily over a 7-day course to patients with UC was associated with short-term improvement in disease activity scores, with clinical effects being observed within 21 days and associated with reductions in C-reactive protein and stool calprotectin. AP enzyme treatment was well tolerated and nonimmunogenic. (Inflamm Bowel Dis 2009;)
Babesiosis in a patient on infliximab for Crohn's disease
Garret Cullen, Bruce E. Sands, Vijay Yajnik Mon, 02 Nov 2009 10:09:00 -0000
No abstract.
Campylobacter concisus and other Campylobacter species in children with newly diagnosed Crohn's disease
Si Ming Man, Li Zhang, Andrew S. Day, Steven T. Leach, Daniel A. Lemberg, Hazel Mitchell Mon, 02 Nov 2009 10:15:00 -0000
Campylobacter concisus and other members of the Campylobacter genus have recently been suggested as possible etiological agents of Crohn's disease (CD). To further investigate this issue we determined the prevalence of these organisms in pediatric patients newly diagnosed with CD.DNA was extracted from fecal specimens collected from 54 children with CD, 27 noninflammatory bowel disease (non-IBD), and 33 healthy controls and subjected to polymerase chain reaction (PCR) sequencing.Detection of C. concisus DNA using a newly developed PCR assay targeting the 16S rRNA gene of C. concisus showed that 65% (35/54) of fecal samples from CD children were positive, a prevalence significantly higher than that in the healthy (33%, 11/33, P = 0.008) and non-IBD controls (37%, 10/27, P = 0.03). The prevalence of all Campylobacter DNA using genus-specific primers in children with CD was 72% (39/54), which was significantly higher than the 30% (10/33, P = 0.0002) and 30% (8/27, P = 0.0003) observed in healthy and non-IBD controls, respectively.Given the strengthening evidence for a significantly higher prevalence of C. concisus and other non-jejuni Campylobacter species in pediatric CD, investigation into the role of these non-jejuni Campylobacter species in the initiation of human IBD is clearly a priority. (Inflamm Bowel Dis 2009;)

Subscribe to Gastroenterology RSS feed